4.4 Article

Apigenin inhibits isoproterenol-induced myocardial fibrosis and Smad pathway in mice by regulating oxidative stress and miR-122-5p/155-5p expressions

Journal

DRUG DEVELOPMENT RESEARCH
Volume 83, Issue 4, Pages 1003-1015

Publisher

WILEY
DOI: 10.1002/ddr.21928

Keywords

apigenin; miR-122-5p; miR-155-5p; myocardial fibrosis; TGF-beta 1/Smads

Funding

  1. Applied Foundational Research of Medical and Health Care of Suzhou City [SYSD2019190, SYS2018088]
  2. Science and Technology Development Fund of Nanjing Medical University [NMUB2020261]
  3. Science and Technology Development Fund of Suzhou for Youth [KJXW2020038]
  4. Scientific Research Project of Gusu College, Nanjing Medical University [GSKY20210202]

Ask authors/readers for more resources

Apigenin, derived from Apium graveolens, effectively inhibits TGF-beta 1-induced cardiac fibroblasts differentiation and collagen synthesis. It also prevents isoproterenol-induced myocardial fibrosis in mice by regulating miR-122-5p and miR-155-5p expression and modulating HIF-1 alpha, c-Ski, Smads, and NF-kappa B/TGF-beta 1 signaling pathway. Moreover, apigenin enhances antioxidant ability to exert its antifibrotic effects.
Apigenin, a flavonoid isolated from Apium graveolens, is an effective natural active ingredient that inhibits transforming growth factor-beta 1 (TGF-beta 1)-induced cardiac fibroblasts (CFs) differentiation and collagen synthesis. However, its effects on isoproterenolinduced myocardial fibrosis in mice remain unknown. This study aimed to examine the effect of apigenin in the prevention of myocardial fibrosis. A mouse model of myocardial fibrosis induced by isoproterenol was established, and the mice were given apigenin 75-300 mg/kg orally for 40 days. The results showed that the heart weight coefficient, myocardial hydroxyproline, collagen accumulation, and malondialdehyde levels in the apigenin-treated groups were significantly reduced. In contrast, the activity of myocardial superoxide dismutase and glutathione peroxidase were significantly enhanced. The results of real-time quantitative polymerase chain reaction and western blot assays showed that apigenin could significantly upregulate the expressions of myocardial microRNA-122-5p (miR-122-5p), c-Ski, and Smad7 and downregulate the expressions of myocardial miR-155-5p, alpha-smooth muscle actin, collagen I/III, NF-kappa B, TGF-beta 1, hypoxia-inducible factor-1 alpha (HIF-1 alpha), Smad2/3, and p-Smad2/3. In vitro, the differentiation and extracellular matrix production, as well as TGF-beta 1/Smads axis, were further reduced after treatment of miR-122-5p mimic or miR-155-5p inhibitor-transfected and TGF-beta 1-stimulated CFs with apigenin. These results suggested that apigenin increased the expression of miR-122-5p and decreased the expression of miR-155-5p, which subsequently downregulated and upregulated the target genes HIF-1 alpha and c-Ski, respectively. Furthermore, apigenin administration downregulated TGF-beta 1-induced Smad2/3 and upregulated Smad7. In addition, it reduced the NF-kappa B/TGF-beta 1 signaling pathway axis by increasing antioxidant ability to exert the antifibrotic effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available